The year 2024 saw the U.S. stock market make new records, with major indices breaching key milestones. While many stocks ...

The global market for barrett’s esophagus with dysplasia treatment is poised for significant growth, with a projected ...

Shares of Merck & Co. Inc. MRK inched 0.08% higher to $99.45 Tuesday, on what proved to be an all-around favorable trading ...

A Fremont pharmaceutical company received an investment of approximately $50 million — about $3.56 per share — in a private ...

Treatment Market. According to a recent market analysis conducted by Future Market Insights, the global molluscum contagiosum ...

Merck, a leading global pharmaceutical company that produces a range of medicines, vaccines, and animal healthcare products, ...

Sanofi is handing SK bioscience 50 million euros ($52 million) as the longtime partners take their next-gen pneumococcal ...

About 87.5% of patients treated with the drug were alive after six years, compared to 83.2% who received a placebo.

Jefferies analyst Akash Tewari has maintained their bullish stance on MRK stock, giving a Buy rating on December 18.Pick the best stocks and ...

Novo Nordisk posts disappointing update related to its new weight loss drug CagriSema. Novo Nordisk stock is now down 25% ...

Merck & Co Inc (MRK) stock saw a modest uptick, ending the day at $99.52 which represents a slight increase of $1.18 or 1.20% from the prior close of $98.34. The stock opened at $98.56 and touched a ...

Perhaps PD-1 inhibitors just aren’t for ovarian cancer after all. | Merck's and GSK's similar overall survival setbacks ...